These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7475755)

  • 21. Sleep attacks and Parkinson's disease treatment.
    Ferreira JJ; Galitzky M; Montastruc JL; Rascol O
    Lancet; 2000 Apr; 355(9212):1333-4. PubMed ID: 10776750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

  • 23. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of amino acid ergot alkaloids on glutamate transport via human glutamate transporter hGluT-1.
    Yamashita H; Kawakami H; Zhang YX; Tanaka K; Nakamura S
    J Neurol Sci; 1998 Feb; 155(1):31-6. PubMed ID: 9562319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis.
    Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A
    J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice.
    Mohanasundari M; Srinivasan MS; Sethupathy S; Sabesan M
    J Neurol Sci; 2006 Nov; 249(2):140-4. PubMed ID: 16876826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of early Parkinson's disease.
    Koller WC
    Neurology; 2002 Feb; 58(4 Suppl 1):S79-86. PubMed ID: 11909989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Ahlskog JE
    Neurology; 2003 Feb; 60(3):381-9. PubMed ID: 12580184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydroergocryptine in the treatment of Parkinson's disease.
    Bonuccelli U; D'Antonio P; D'Avino C; Piccini P; Muratorio A
    J Neural Transm Suppl; 1995; 45():239-45. PubMed ID: 8748631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of motor function in early Parkinson disease by safinamide.
    Stocchi F; Arnold G; Onofrj M; Kwiecinski H; Szczudlik A; Thomas A; Bonuccelli U; Van Dijk A; Cattaneo C; Sala P; Fariello RG;
    Neurology; 2004 Aug; 63(4):746-8. PubMed ID: 15326260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine D1 receptor agonists as antiparkinson drugs.
    Mailman RB; Nichols DE
    Trends Pharmacol Sci; 1998 Jul; 19(7):255-6. PubMed ID: 9703756
    [No Abstract]   [Full Text] [Related]  

  • 35. Do dopamine agonists provide neuroprotection?
    Yamamoto M
    Neurology; 1998 Aug; 51(2 Suppl 2):S10-2. PubMed ID: 9711974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pharmacological profiles and clinical effects of ropinirole hydrochloride (ReQuip)].
    Arai H; Minami J
    Nihon Yakurigaku Zasshi; 2007 Oct; 130(4):313-9. PubMed ID: 17938518
    [No Abstract]   [Full Text] [Related]  

  • 38. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview.
    Stern MB
    Neurology; 1997 Jul; 49(1 Suppl 1):S2-9. PubMed ID: 9222270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment options for early Parkinson's disease.
    Stacy M; Brownlee HJ
    Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Equivalent doses of ropinirole and bromocriptine.
    Jost WH
    Eur J Neurol; 1999 Sep; 6(5):618. PubMed ID: 10866496
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.